Status:
COMPLETED
Immunomodulation Therapy for Urinary Tract Infections
Lead Sponsor:
Swiss Paraplegic Research, Nottwil
Collaborating Sponsors:
Swiss Spinal Cord Injury Cohort Study (SwiSCI)
Conditions:
Spinal Cord Injuries
Urinary Tract Infections
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
Urinary tract infections (UTI) represent one of the most common morbidities in individuals with spinal cord injury (SCI) and reason for re-hospitalization. The consequences of recurrent UTI are a decr...
Eligibility Criteria
Inclusion
- acute SCI (within 8 weeks after SCI)
- onset of SCI within 72h
- age from 18 to 70 years
- informed consent as documented by signature
Exclusion
- known hypersensitivity to investigational product,
- other immunomodulation therapy,
- immunosuppressant therapy,
- oncological condition or therapy,
- autoimmune diseases, nephropathy, bladder stones,
- women who are pregnant (pregnancy test) or breast feeding,
- participation in another study with an investigational drug within the 30 days preceding and during the present study
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2023
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04049994
Start Date
June 1 2020
End Date
October 31 2023
Last Update
November 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Swiss Paraplegic Centre
Nottwil, Canton of Lucerne, Switzerland, 6207